- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07823088
Open Label Safety Investigation of Solutio™ Tumescent Catheter
A Prospective, Open Label Investigation of Safety of the Solutio™ Tumescent Catheter for Endothermal Ablation of Varicose Veins
The goal of this clinical investigation is to evaluate safety of the Solutio™ catheter when administering tumescent anesthesia before treatment with endothermal ablation in adults above the age of 18, who suffer from unilateral insufficiency of the great saphenous vein (GSV).
Main question(s) to answer is:
Safety evaluated through reported Adverse Device Effects (ADEs) and Serious Adverse Device Effects (SADEs).
Incidence of Adverse Events (AE), Adverse Device Effects (ADE), Serious Adverse Events (SAE), Serious Adverse Device Effects (SADE), and device deficiency (DD) throughout the investigation.
All investigation participants will:
- Undergo screening, including medical history, physical examination, and vein mapping with Doppler ultrasound.
- Have their Great Saphenous Vein (GSV) treated using Seldinger technique under ultrasound guidance.
- Receive tumescent anesthesia injected from inside the vein into the perivascular tissue at selected sites along the vein, using the investigational Solutio™ catheter under ultrasound guidance.
- Undergo endothermal ablation, Endovenous Laser Ablation (EVLA), or Radiofrequency Ablation (RFA).
- Be followed up for 28 days through scheduled phone calls (Day 1, Day 14 ±2) and clinic visits (Day 7 ±1, Day 28 ±2) to assess adverse events, pain, patient comfort, and undergo physical/clinical examinations and ultrasound examinations of the treated area.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Ingegerd W Dalfelt, SRN, BSc.
- Número de telefone: +46708433348
- E-mail: ingegerd.dalfelt@gmail.com
Estude backup de contato
- Nome: Cathrin Johansson, BSc
- Número de telefone: +46708548834
- E-mail: cathrin.johansson@medvasc.se
Locais de estudo
-
-
-
Halmstad, Suécia, 301 85
- Hallands sjukhus
-
Contato:
- Karin Ludwigs, MD
- Número de telefone: +46 (0)35 14 77 53
- E-mail: Karin.Ludwigs@regionhalland.se
-
Malmö, Suécia, 21135
- Scandinavian Venous Centre
-
Contato:
- Karin Ludwigs, MD
- Número de telefone: +46707382447
- E-mail: karin.ludwigs@svcgoteborg.se
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Male or Female >18 years old.
- Subject diagnosed with venous insufficiency in the Great Saphenous Vein from the groin to the proximal 1/3 of the lower leg and with a Clinical Etiological Anatomical Pathophysiological (CEAP) classification of 2 or higher.
- Subject is scheduled for an EVLA or RFA procedure for a unilateral insufficiency of the GSV.
- Subject accepts to be treated with endothermal ablation as a standalone method.
- Subject accepts to be treated without any sedation.
- Subject is willing and able to provide written informed consent.
Exclusion Criteria:
- Considered as being of high risk due to comorbidity in the opinion of the investigator.
- Subject with known and confirmed coagulation defects.
- Subject on anticoagulant treatment.
- Subject who simultaneously needs to be treated with other supplemental techniques such as e.g., foam sclerotherapy, ligation, and phlebectomy.
- Subject with GSV insufficiency in the distal 2/3 of the lower leg.
- Subject, who demands full sedation, or general anesthesia.
- Subject with known allergy to any of the tumescent and/or anesthetizing agents that will be used (per local standard practice) during the endothermal ablation procedure.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Solutio™ catheter used to administrate tumescence during endothermal ablation of varicose veins
Administration of tumescence from inside the vein to the surrounding tissue, via Solutio™ catheter during endothermal ablation of varicose veins.
|
The Solutio™ catheter presents a technique that allows for tumescent anesthesia injections to be administered at selected sites along the vein, from inside the vein to the surrounding tissue. The purpose of the Solutio™ catheter is to prevent the pain associated with multiple injections, through sensitive skin layers along the inner side of the leg, administered prior to ablation. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Safety related to the procedure using the Solutio™ catheter.
Prazo: 28 days
|
Safety evaluated by recording the number and type of adverse device effects (ADEs) and serious adverse device effects (SADEs) related to the procedure using the Solutio™ catheter.
|
28 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patient experience of pain
Prazo: 28 days
|
The patient will rate their experience of pain at follow up visits at the clinic and via phone contacts.
A Visual Analogue Scale (VAS) measures pain intensity.
The scale consists of a 100 mm line, with two end points representing 0 = "no pain" and 100 = "worst pain imaginable".
The patient will be asked to make a mark across the line according to the maximum experienced pain to indicate their pain at given timepoints.
At phone contacts the patient is asked a standard question to rate their pain with a number from 0 to 10, a Numeric Rating Scale (NRS), where 0 = "no pain" and 10 = "worst pain imaginable"
|
28 days
|
|
Physician feedback
Prazo: 1 day
|
After the end of the procedure, the physician is asked to provide their feedback, assessment about 10 different aspects during the procedure.
They will answer with a 4-grade scale (1 is excellent, 2 is good, 3 is fair, 4 is impossible /inadequate).
Acceptable score is ≤3 for each question.
|
1 day
|
|
Patient experience of pain
Prazo: 28 days
|
At phone contacts the patient is asked a standardized question to rate their pain with a number from 0 to 10, a Numeric Rating Scale (NRS), where 0 = "no pain" and 10 = "worst pain imaginable".
|
28 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Michael Akesson, MD, MedVasc AB
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CSDPR901
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .